10-K: Rigel Pharmaceuticals Reports Full Year 2023 Results, Expands Portfolio with Gavreto Acquisition

Rigel Pharmaceuticals reports a 24% increase in TAVALISSE sales and a significant jump in REZLIDHIA sales, while also acquiring rights to GAVRETO in the US.

Summary

• Rigel Pharmaceuticals reported a 24% increase in TAVALISSE net product sales, reaching $93.7 million in 2023, driven by increased patient numbers and price adjustments.
• REZLIDHIA net product sales saw a substantial increase to $10.6 million in 2023, compared to $0.9 million in 2022, due to the start of commercialization in December 2022.
• The company entered an agreement to acquire GAVRETO in the US for $15 million upfront, plus potential milestone payments and royalties, with commercialization expected in the third quarter of 2024.
• Rigel is advancing its IRAK1/4 inhibitor program with a Phase 1b trial for R289 in lower-risk MDS, with preliminary results expected by the end of 2024.
• Strategic collaborations with MD Anderson and CONNECT are underway to expand the evaluation of REZLIDHIA in AML, other hematologic cancers, and glioma.
• Lilly is progressing R552, a RIPK1 inhibitor, with a Phase 2a trial in rheumatoid arthritis, and Rigel has opted out of co-funding R552 development, but retains the right to opt-in.
• A corrected analysis of the FOCUS Phase 3 trial for fostamatinib in COVID-19 showed positive results, but the company decided not to pursue an EUA or sNDA.
• A patent infringement lawsuit against Annora regarding a generic version of TAVALISSE is ongoing.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with strong sales growth and strategic acquisitions, but also acknowledges risks and challenges, resulting in a moderately positive sentiment.

Positives

• TAVALISSE sales continue to grow, indicating strong market acceptance.
• REZLIDHIA sales are rapidly increasing following its commercial launch.
• The acquisition of GAVRETO expands Rigel's commercial portfolio and leverages existing infrastructure.
• The IRAK1/4 inhibitor program is progressing with a Phase 1b trial.
• Strategic collaborations with MD Anderson and CONNECT expand the potential of REZLIDHIA.
• Lilly is advancing R552, a RIPK1 inhibitor, into Phase 2a trials.

Negatives

• The company decided not to pursue an EUA or sNDA for fostamatinib in COVID-19 despite positive results after correcting a statistical error.
• A patent infringement lawsuit against Annora regarding a generic version of TAVALISSE is ongoing, which could lead to future competition.
• The company has a history of operating losses and may not achieve profitability in the near future.

Risks

• The commercial success of TAVALISSE, REZLIDHIA, and GAVRETO is critical to the company's future.
• Clinical trials may not meet endpoints or lead to regulatory approvals.
• The company's strategy to expand its pipeline may not be successful.
• Unfavorable pricing regulations or reimbursement practices could harm the business.
• The company relies on third-party manufacturers and distributors.
• The company is subject to stringent healthcare and privacy regulations.
• Generic versions of the company's products could harm the business.
• Unforeseen safety issues could emerge with the company's products.
• The company may need to raise additional capital in the future.
• The company is subject to intense competition from other pharmaceutical and biotechnology companies.

Future Outlook

Rigel expects to complete the transition of the GAVRETO asset and start recognizing product sales in the third quarter of 2024. The company also plans to expand its development pipeline and commercialize REZLIDHIA outside of the US through collaborations.

Management Comments

• Management believes GAVRETO will be highly synergistic with the current product portfolio.
• Management expects to leverage the existing commercial infrastructure to ensure continued access to GAVRETO for patients.
• Management aims to expand the portfolio with additional commercial products and/or additional candidates for the development pipeline.

Industry Context

The acquisition of GAVRETO positions Rigel in the competitive RET inhibitor market, where it will compete with Lilly's selpercatinib. The company is also expanding its presence in the hematology and oncology space, aligning with broader industry trends in targeted therapies.

Comparison to Industry Standards

• Rigel's 24% increase in TAVALISSE sales is a positive sign, but it is important to compare this growth rate to other companies in the ITP market, such as Novartis (PROMACTA) and Amgen (Nplate).
• The rapid growth of REZLIDHIA sales is encouraging, but it is important to compare its market penetration to that of Servier's TIBSOVO in the mIDH1 R/R AML space.
• The acquisition of GAVRETO is a strategic move, but its success will depend on Rigel's ability to compete with Lilly's selpercatinib and other therapies in the RET fusion-positive NSCLC and advanced thyroid cancer markets.
• The progress of Rigel's IRAK1/4 inhibitor program is promising, but it is important to compare its clinical trial results to those of other companies developing similar inhibitors for MDS.
• The strategic collaborations with MD Anderson and CONNECT are valuable, but it is important to assess the impact of these collaborations on the development timelines and costs of REZLIDHIA.

Legal Proceedings

• A patent infringement lawsuit against Annora regarding a generic version of TAVALISSE is ongoing.

Stakeholder Impact

• Shareholders may benefit from the increased sales and strategic acquisitions.
• Employees may benefit from the company's growth and expansion.
• Patients may benefit from the availability of new treatment options.
• Customers may benefit from the company's expanded product portfolio.

Next Steps

• Complete the transition of the GAVRETO asset and start recognizing product sales in the third quarter of 2024.
• Continue the Phase 1b trial of R289 in lower-risk MDS and report preliminary results by the end of 2024.
• Advance strategic collaborations with MD Anderson and CONNECT to expand the evaluation of REZLIDHIA.
• Continue to monitor the progress of R552 with Lilly.
• Continue to monitor the patent infringement lawsuit against Annora.

Key Dates

Keywords

TAVALISSE, fostamatinib, REZLIDHIA, olutasidenib, GAVRETO, pralsetinib, IRAK1/4 inhibitor, R289, RIPK1 inhibitor, R552, AML, MDS, NSCLC, thyroid cancer, hematology, oncology